CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Veru Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Veru Inc
2916 N. MIAMI AVENUE, SUITE 1000
Phone: (312) 595-9123p:312 595-9123 MIAMI, FL  33127  United States Ticker: VERUVERU

On February 15, 2024, the Audit Committee of the Board of Directors of Veru Inc., based on the recommendation of management, concluded that the company’s previously issued consolidated financial statements as of and for the year ended September 30, 2023 should no longer be relied upon due to errors in overestimating certain research and development expenses. The company’s estimated research and development expenses recorded were higher than the actual expenses that were incurred. The net result of these research and development estimated expenses being recorded at too high of an amount is that the company’s cash on hand is expected to last longer than initially stated. The company is evaluating the impact the error has on previous fiscal periods, which also could include the audited financial statements as of and for the year ended September 30, 2022, as well as the unaudited quarterly financial statements within the years ended September 30, 2023 and 2022.

Business Summary
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20239/30/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer Mitchell S.Steiner 63 3/1/2018 10/31/2016
Vice Chairman of the Board, Chief Corporate Officer HarryFisch 65 3/1/2018 10/31/2016
Chief Financial Officer, Chief Administrative Officer MicheleGreco 65 3/1/2018 1/1/2013
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
THE FEMALE HEALTH COMPANY (UK) PLC 3 WESTERN AVENUE BUSINESS PARK MANSFIELD ROAD UK

Business Names
Business Name
Aspen Park Pharmaceuticals, Inc.
Badger Acquisition Sub, Inc.
FHCO
8 additional Business Names available in full report.

General Information
Number of Employees: 189 (As of 10/31/2023)
Outstanding Shares: 146,381,186 (As of 1/16/2024)
Shareholders: 153
Stock Exchange: NASD
Federal Tax Id: 391144397
Fax Number: (312) 595-9122
Email Address: info@femalehealth.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024